Healthy Adult
Conditions
Interventions
Intake of test food for 12 consecutive weeks
Intake of control placebo food for 12 consecutive weeks
Sponsors
Miura Clinic, Medical Corporation Kanonkai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy men and women aged 20 to 64 (2) Individuals with dry skin and scalp (3) Individuals who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing
Exclusion criteria
Exclusion criteria: (1) Individuals with a history of mental illness, diabetes, liver disease, renal diseases, gastrointestinal disease, cardiac disease, respiratory disease, peripheral vascular disease, or other serious disease. (2) Individuals who have undergone gastrointestinal surgery. (3) Individuals showing abnormal liver and kidney function test values. (4) Individualswith a current medical condition. (5) Individuals with skin symptoms. (6) Individuals who are allergic to food and drugs. (7) Individuals with symptoms of anemia. (8) Females wishing to become pregnant while participating in this study, pregnant (including those who may be pregnant) or lactating female subjects. (9) Individuals who participate in strenuous sports and subjects who are trying to lose weight. (10) Individuals with extremely irregular eating habits. (11) Individuals who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the study period. (12) Individuals who are continuously treated with medications (including OTC, prescription drugs). (13) Individuals who drink more than 40 g of average daily pure alcohol. (14) Individuals who smoke an average of 21 or more cigarettes a day. (15) Individuals who are currently participating in other clinical studies or are scheduled to participate in research at the start of this study. (16) Individuals judged by the principal investigator or the associate investigator to be inappropriate for the examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Moisture content of stratum corneum Transepidermal water loss Skin elasticity | — |
Secondary
| Measure | Time frame |
|---|---|
| Scalp elasticity(hardness) Scalp transdermal water evaporation rate | — |
Countries
Japan
Contacts
Public ContactMakoto Terashima
Makoto Terashima Clinical Trial Division
Outcome results
None listed